Dyslipidemia and Chronic Kidney Disease

Parmar, Jigar A; Joshi, Anant; Chakrabarti, Manish

doi:10.15373/22778179/may2014/123

Cited by 12 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the Kidney Disease Outcomes Quality Initiative (K/DOQI), CKD is defined as kidney damage or a decreased kidney glomerular filtration rate (GFR) of <60 mL/min/1.73m 2 for at least 3 months. 1,2 Patients with CKD, particularly those with end-stage renal disease (ESRD) who are treated with hemodialysis (HD) or peritoneal dialysis (PD) or those treated with renal transplantation, are at increased risk of developing cardiovascular disease (CVD). 3 It is more likely that patients with CKD will die because of CVD than develop ESRD and have the need for renal replacement therapy.…”

Section: Introductionmentioning

confidence: 99%

“…However, CKD, with both dialysis and transplantation, is associated with specific qualitative and quantitative lipid abnormalities, resulting in specific dyslipidemia (Table 1). 1,3,6 The relationship between dyslipidemia and CVD morbidity and mortality in this specific population group is not as clear as that in the general population. 7 Specific abnormalities in the lipoprotein metabolism, caused by an inappropriate activity of some key enzymes and metabolic pathways, develop in the early stage of renal failure and result in dyslipidemia which presents a risk factor for the atherosclerosis development.…”

mentioning

confidence: 95%

“…Along with CKD progression, metabolic abnormalities may progress further, contributing to atherosclerotic changes and adversely affecting renal function. 1,4,7 According to the current evidence, lipid-lowering medications are effective in reducing CVD mortality and morbidity in the general population. Recent studies suggest that these medications may have the same beneficial effect in both CKD and the transplant population.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Dyslipidemia in patients with chronic kidney disease: etiology and management

Mikolašević¹,

Žutelija²,

Mavrinac³

et al. 2017

IJNRD

197

149

View full text Add to dashboard Cite

Abstract:Patients with chronic kidney disease (CKD), including those with end-stage renal disease, treated with dialysis, or renal transplant recipients have an increased risk for cardiovascular disease (CVD) morbidity and mortality. Dyslipidemia, often present in this patient population, is an important risk factor for CVD development. Specific quantitative and qualitative changes are seen at different stages of renal impairment and are associated with the degree of glomerular filtration rate declining. Patients with non-dialysis-dependent CKD have low high-density lipoproteins (HDL), normal or low total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol, increased triglycerides as well as increased apolipoprotein B (apoB), lipoprotein(a) (Lp (a)), intermediate-and very-low-density lipoprotein (IDL, VLDL; "remnant particles"), and small dense LDL particles. In patients with nephrotic syndrome lipid profile is more atherogenic with increased TC, LDL, and triglycerides. Lipid profile in hemodialysis (HD) patients is usually similar to that in non-dialysis-dependent CKD patients. Patients on peritoneal dialysis (PD) have more altered dyslipidemia compared to HD patients, which is more atherogenic in nature. These differences may be attributed to PD per se but may also be associated with the selection of dialytic modality. In renal transplant recipients, TC, LDL, VLDL, and triglycerides are elevated, whereas HDL is significantly reduced. Many factors can influence post-transplant dyslipidemia including immunosuppressive agents. This patient population is obviously at high risk; hence, prompt diagnosis and management are required to improve their clinical outcomes. Various studies have shown statins to be effective in the cardiovascular risk reduction in patients with mild-to-moderate CKD as well as in renal transplant recipients. However, according to recent clinical randomized controlled trials (4D, A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Dialysis: an Assessment of Survival and Cardiovascular Events, and Study of Heart and Renal protection), these beneficial effects are uncertain in dialyzed patients. Therefore, further research for the most suitable treatment options is needed.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 95%

mentioning

confidence: 99%

See 1 more Smart Citation

Dyslipidemia in patients with chronic kidney disease: etiology and management

Mikolašević¹,

Žutelija²,

Mavrinac³

et al. 2017

IJNRD

197

149

View full text Add to dashboard Cite

show abstract

“…От 40 до 50% пациентов с терминальной ХБП имеют уровень ТГ>2,26 ммоль/л, ЛПНП>3,4 ммоль/л. Липопротеиновый профиль при ХБП характеризуется количественными и качественными отклонениями от нормы, которые еще больше усугубляются по мере снижения СКФ, достигая максимальной выраженности у пациентов на терминальной стадии болезни почек [5][6][7][8]. Для большинства пациентов с ХБП 3-5 стадии характерна смешанная дислипидемия, а липидной профиль характеризуется высокой атерогенностью с изменениями всех фракций липопротеинов.…”

Section: материал и методыunclassified

Dyslipidemia in Kidney Receiver

Мартиросян

Космачева

2019

Innovative Medicine of Kuban

View full text Add to dashboard Cite

Background Kidney transplantation is the gold standard of treatment in patients with a terminal renal failure. Nevertheless, the main reason for death of recipients, loss of the renal allograft is cardiovascular disease, and disorder of lipid profile remains one of the most significant risk factors and progressing of cardiovascular pathology. Aim We estimated dyslipidemia dynamics before and at various terms after kidney transplantation and we tried to reveal interrelation of disorder of lipid metabolism with renal transplant functioning. Material and Methods The retrospective observational research of the cohort in a uniform group of lipid profile dynamics observation in terms before kidney transplantation and in 6, 12 and 36 months of two hundred liver recipients at the age of 40.18±10.33 years has been conducted. Among those there was 41.5% female patients and 58.5% male patients. The statistical analysis was carried out by means of STATISTICA 10.0 program. The critical significance value while checking statistical hypotheses in this research was accepted equal 0.05. The method of multifactorial logistic regression was applied to search factors associated with a dyslipidemia. Results Level of the general cholesterol before transplantation was 4.34±1.21 mmol/l, in comparison with an initial indicator of the general cholesterol increase in dynamics in 12 and 36 months was 17.5% (р = 0.02), 22.9% (р = 0.03), respectively. The LDL level in the studied cohort of recipients was around 2.36±1.21 mmol, and in 6 months it increased by 12.3% (р = 0.02), in a year for 5.9% (р = 0.21) and 36 months later differed from initial on 14.8 (р = 0.01). In three years after transplantation period LPVP decreased by 12.3% (р = 0.01). In comparison with initial level before transplantation they increased on 8,9% (р = 0,03) и 16,7% (р =0,01) in 12 and 36 months, respectively. The factors associated with dyslipidemia is the age - 1.21-1.7 (р<0.02), diabetes – 1.1-1.5 (р<0.03), the speed of glomerular filtration (kg/sq.m) - 1.23-1.32 (р<0.02), proteinuria (g/l)-1.55-2.1 (р<0.001), the left ventricle myocardium mass index (kg/sq.m)-1.23-1.55 (р <0.03), hemoglobin (g/l)-1.1-1.23 (р<0.04), systolic arterial blood pressure-1.2-2.1 (р<0.001), diastolic arterial blood pressure – 1.1-2.2 (р<0.002). The negative correlational interrelation between the level of cholesterol and survival of the renal allograft, estimated on the speed of glomerular filtration was revealed (р = 0.003). Level of the general cholesterol was a significant independent predictor for survival and functioning of the renal allotransplantat in 3 years after transplantation. Conclusion The progressing disorder of a lipid profile in the long-term post-transplantation period was revealed, dyslipidemia is a significant modified predictor of successful kidney transplantation.

show abstract

“…High affinity for macrophages results in the accumulation of cholesterol and the formation of foam cells in the vascular walls, finally resulting in the development of accelerated atherosclerotic plaques. [26,27] Abnormalities in the lipid metabolism are found to be most common among end stage renal failure patients. Triglycerides and high cholesterol components affect the blood circulation pool by formation of fat plaques on major blood vessels.…”

Section: Introductionmentioning

confidence: 99%

To Analyse the Pattern of Lipid Profile in Patients of Chronic Kidney Disease

Verma¹,

Singh²

2018

AIMDR

View full text Add to dashboard Cite

Background: Chronic kidney disease (CKD), is a progressive and irreversible deterioration in the function of kidney over months to years,2 which is defined as"glomerular filtration rate (GFR) lesser than 60 ml/min with protenuria for 3 months".3 It leads to various biochemical disturbances and numerous clinical symptoms and signs.4Some of the associated changes are abnormalities in haematology parameters, heart related issues, disturbances of gastrointestinal tract, neurologic disorder, osteodystrophy, skin related problems and sexual dysfunction. Dyslipidemias are a common among CRF patients. The disturbances of lipoprotein metabolism are seen in early stages of CRF and can follow decrement pattern that follows the renal function deterioration. Aim and Objectives This study was aimed to analyse the pattern of lipid profile among the dif. Methods: The study was cross-sectional observational study conducted on 100 patients either attending or being admitted in the department of Internal Medicine, TMMC & RC, TMU , Moradabad, U.P., INDIA, which were in line with the inclusion criteria. Result & Conclusion: Our results indicated that patients undergoing CRF show important abnormalities of lipid metabolism which could contribute to atherosclerosis and cardiovascular disease and may increase the morbidity and mortality in these patients.

show abstract

Dyslipidemia and Chronic Kidney Disease

Cited by 12 publications

References 0 publications

Dyslipidemia in patients with chronic kidney disease: etiology and management

Dyslipidemia in patients with chronic kidney disease: etiology and management

Dyslipidemia in Kidney Receiver

To Analyse the Pattern of Lipid Profile in Patients of Chronic Kidney Disease

Contact Info

Product

Resources

About